Although neutralization of TNF-α by monoclonal antibodies can mitigate shock and increase survival in LPS-induced experimental septic shock models4, targeted TNF-α therapies have not shown benefits in clinical trials and can even lower patient survival rates by interfering with anti-infection defenses3,4,7. This evidence concerns the gene TNF and infection.